Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - gabapentin -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - gabapentin 100mg - capsule - 100 mg - active: gabapentin 100mg excipient: capsule white 0999 magnesium stearate maize starch mannitol purified talc tekprint black sw-9008 tekprint black sw-9009 - indicated for the treatment of partial seizures with or without secondarily generalised tonic-clonic seizures, in adults and children age three years and above who have not achieved adequate control with standard anti-epileptic medicines.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - gabapentin 300mg - capsule - 300 mg - active: gabapentin 300mg excipient: capsugel ivory 4007 magnesium stearate maize starch mannitol purified talc tekprint black sw-9008 tekprint black sw-9009 - indicated for the treatment of partial seizures with or without secondarily generalised tonic-clonic seizures, in adults and children age three years and above who have not achieved adequate control with standard anti-epileptic medicines.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - gabapentin 400mg - capsule - 400 mg - active: gabapentin 400mg excipient: capsugel orange 3294 magnesium stearate maize starch mannitol purified talc tekprint black sw-9008 tekprint black sw-9009 - indicated for the treatment of partial seizures with or without secondarily generalised tonic-clonic seizures, in adults and children age three years and above who have not achieved adequate control with standard anti-epileptic medicines.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - gabapentin 600mg - film coated tablet - 600 mg - active: gabapentin 600mg excipient: crospovidone hyprolose magnesium stearate mannitol opacode black s-1-17734 opadry clear 20a59015 poloxamer 407 purified talc purified water   - indicated for the treatment of partial seizures with or without secondarily generalised tonic-clonic seizures, in adults and children age three years and above who have not achieved adequate control with standard anti-epileptic medicines.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - gabapentin 800mg - film coated tablet - 800 mg - active: gabapentin 800mg excipient: crospovidone hyprolose magnesium stearate mannitol opacode black s-1-17734 opadry clear 20a59015 poloxamer 407 purified talc purified water   - indicated for the treatment of partial seizures with or without secondarily generalised tonic-clonic seizures, in adults and children age three years and above who have not achieved adequate control with standard anti-epileptic medicines.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rivastigmine tartrate 2.4mg (rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine); rivastigmine tartrate 2.4mg (rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine) - capsule - 1.5 mg - active: rivastigmine tartrate 2.4mg (rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv purified water sodium laurilsulfate titanium dioxide active: rivastigmine tartrate 2.4mg (rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv opacode red s-1-1666 purified water sodium laurilsulfate titanium dioxide - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine); rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) - capsule - 3 mg - active: rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv purified water sodium laurilsulfate titanium dioxide active: rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv opacode red s-1-1666 purified water sodium laurilsulfate titanium dioxide - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.